Concepedia

Luigi Manenti

LM

14

Publications

1.2K

Citations

14

H-Index

2003

Active since

Affiliations

National Cancer Centre Singapore(Current)

Novartis (Switzerland)

National Taiwan University Hospital

Mario Negri Institute for Pharmacological Research

Sun Yat-sen University

Luigi Manenti is an author at National Cancer Centre Singapore specializing in medicine, pathology, and cancer therapeutics.

Top concepts

Publications per year

2003–2022

14

Publications

14

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Clinical Cancer Research · 2021 · 335 citations · Full text

Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Dorina Belotti, Paola Paganoni, Luigi Manenti et al. · PubMed · 2003 · 320 citations

, , +17

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Luis Paz‐Ares, Carlos Gomez‐Roca, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2011 · 81 citations

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon et al. · Clinical Cancer Research · 2022 · 65 citations · Full text

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Angela Garofalo, Elitza Naumova, Luigi Manenti et al. · PubMed · 2003 · 63 citations

Rows per page

1–5 of 14